Immune-mediated oligodendrocyte injury in multiple sclerosis: molecular mechanisms and therapeutic interventions
- PMID: 12803318
Immune-mediated oligodendrocyte injury in multiple sclerosis: molecular mechanisms and therapeutic interventions
Abstract
In this review, new insights into the immunopathogenesis of multiple sclerosis (MS) are discussed, with special focus on the potential mechanisms leading to neuroinflammation in MS--that is, the role of autoreactive T cells, infections, and neurodegenerative events. Oligodendrocytes are considered to be the target of autoimmune inflammation in the CNS of MS patients. Some important features of oligodendrocyte biology are discussed, together with the molecular mechanisms that are potentially involved in oligodendrocyte injury. These include injury mechanisms that might be executed by the adaptive and innate immune system, via cytokines and/or oligodendrocyte receptors, or as a consequence of nitrative and oxidative stress, and excitotoxicity. The mode of cell death of oligodendrocytes in MS is discussed, in addition to the mechanisms of axonal injury as observed in pathology- and imaging-based studies. Finally, recent progress in therapeutic strategies that may interfere with these pathological processes are reviewed, with a focus on repair strategies, such as gene therapy, antibody-mediated remyelination, and stem cell therapy.
Similar articles
-
Multiple sclerosis: a battle between destruction and repair.J Neurochem. 2007 Jan;100(2):295-306. doi: 10.1111/j.1471-4159.2006.04232.x. Epub 2006 Nov 13. J Neurochem. 2007. PMID: 17101032 Review.
-
Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis.Neurology. 2007 May 29;68(22 Suppl 3):S13-21; discussion S43-54. doi: 10.1212/01.wnl.0000275228.13012.7b. Neurology. 2007. PMID: 17548563 Review.
-
Oligodendrocyte/myelin injury and repair as a function of the central nervous system environment.Clin Neurol Neurosurg. 2006 Mar;108(3):245-9. doi: 10.1016/j.clineuro.2005.11.013. Epub 2005 Dec 27. Clin Neurol Neurosurg. 2006. PMID: 16384636 Review.
-
Immunopathogenesis and immunotherapy of multiple sclerosis.Nat Clin Pract Neurol. 2006 Apr;2(4):201-11. doi: 10.1038/ncpneuro0154. Nat Clin Pract Neurol. 2006. PMID: 16932551 Review.
-
Multiple sclerosis and central nervous system demyelination.J Autoimmun. 1999 Nov;13(3):297-306. doi: 10.1006/jaut.1999.0321. J Autoimmun. 1999. PMID: 10550217 Review.
Cited by
-
Clinical implications of neuropathological findings in multiple sclerosis.J Neurol. 2005 Sep;252 Suppl 3:iii10-iii14. doi: 10.1007/s00415-005-2011-5. J Neurol. 2005. PMID: 16170494 Review.
-
The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage.J Clin Invest. 2007 Feb;117(2):448-56. doi: 10.1172/JCI29571. J Clin Invest. 2007. PMID: 17273557 Free PMC article.
-
Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.J Exp Med. 2006 Feb 20;203(2):425-35. doi: 10.1084/jem.20052148. Epub 2006 Feb 13. J Exp Med. 2006. PMID: 16476770 Free PMC article.
-
PERK activation preserves the viability and function of remyelinating oligodendrocytes in immune-mediated demyelinating diseases.Am J Pathol. 2014 Feb;184(2):507-19. doi: 10.1016/j.ajpath.2013.10.009. Epub 2013 Nov 19. Am J Pathol. 2014. PMID: 24269558 Free PMC article.
-
T-Cells and excitotoxicity: HIV-1 and other neurodegenerative disorders.Neuromolecular Med. 2005;7(3):265-73. doi: 10.1385/NMM:7:3:265. Neuromolecular Med. 2005. PMID: 16247186 Review.
Publication types
MeSH terms
LinkOut - more resources
Medical